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Sir,
We read with interest the comments regarding a possible
relationship between female carriers of ataxia telangiectasia (AT)
with susceptibility to low-dose ionising radiation and the
induction of breast cancers in women of screening age.
Although MR mammography does not use ionising radiation, its
use in screening of women at a high risk of breast cancer is
currently being evaluated, both because of the inherent high
sensitivity of the technique, especially in dense pre-menopausal
breast tissue and the safety issues particularly in Li-Fraumeni
syndrome. The UK Magnetic Resonance Imaging for Breast
Screening study (MARIBS) is a multicentre ongoing trial compar-
ing the efficacy of X-ray mammography and MRI as a method for
screening genetically high-risk women aged 35–50 years. This trial
will close in 2005. Results from Kuhl et al (2003) and Kriege et al
(2003) presented recently at the American Society of Clinical
Oncology, relating to similar trials again of genetically high-risk
subjects have indicated promising results. The authors are
unaware of any current trials comparing imaging modalities for
screening the 50–64-year age group, or indeed if such a trial is
contemplated. The results of such a comparison including health
economic issues would need to be very carefully evaluated before
embarking on a long-term follow-up trial to elucidate the risks of
screening using techniques dependent on ionising radiation.
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